The ePitching on November 17, 2020 was designed to connect public and private procurers from the health sector with EIC-funded companies providing medical supply solutions and innovative biotechnologies in response to the COVID-19 pandemic. The event gathered over 50 public and private procurers, and more than 20 EIC-backed SMEs.
The Solnatide project won the ePitching: Best performance and best presentation
Bernhard Fischer, APEPTICO, presented the Solnatide project to the international procurers and has been honoured for his performance and for delivering the best presentation.
Watch a short clip by the European Commission: https://www.facebook.com/epoesterreich/videos/2583720018535945/ #EuropaGegenCovid19
APEPTICO’s Solnatide is a synthetically produced peptide that was developed for treating critically ill ARDS patients. It reduces pulmonary oedemas and combats harmful reactive oxygen radicals. Solnatide has been approved for compassionate use treatment of severe COVID-19 patients with ARDS in various countries, and it is in advanced clinical development driven by Apeptico and the Medical University Vienna. The Solnatide COVID-19 treatment project is the only project „made in Austria“ selected and supported by the European Commission during the EC special H2020 call „Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic (call ID: SC1-PHE-CORONAVIRUS-2020).